X

Trial Profile

A Proof of Concept Study of the Safety and Efficacy of VIB7734 for the Treatment and Prevention of Acute Lung Injury (ALI) in Patients With SARS-CoV-2 Infection

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 22 Dec 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daxdilimab (Primary)
Indications Acute lung injury; COVID-19 pneumonia
Focus Proof of concept; Therapeutic Use
Sponsors Viela Bio

Most Recent Events

16 Jun 2021 Status changed from recruiting to discontinued as study met predefined futility criteria for efficacy endpoints.
19 Apr 2021 Planned End Date changed from 1 Jul 2021 to 1 Oct 2021.
19 Apr 2021 Planned primary completion date changed from 1 Apr 2021 to 1 Jul 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com